Skip to content

Zymeworks ZYME Payments to Acquire Intangible Assets

Payments to Acquire Intangible Assets at other companies

Innoviva, Inc. logo
Innoviva, Inc.INVA
Organon logo
OrganonOGN

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.79B+125%

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireIntangibleAssets.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Zymeworks's payments to acquire intangible assets?
Zymeworks (ZYME) reported payments to acquire intangible assets of $0 in Q1 2026.
How has Zymeworks's payments to acquire intangible assets changed year-over-year?
Zymeworks's payments to acquire intangible assets decreased by 100.0% year-over-year, from $322K to $0.
What is the long-term trend for Zymeworks's payments to acquire intangible assets?
Over 3 years (2022 to 2025), Zymeworks's payments to acquire intangible assets has grown at a -44.9% compound annual growth rate (CAGR), from $4.98M to $831K.